Updated on 1 August 2012
Future of VM202
As a consequence of the aging population and increased risk factors, the number of patients experiencing PDPN, CLI, and CAD, who are unsuitable for or are unresponsive to conventional medical therapy is increasing.
Despite intensive research for new therapeutic strategies, their results have been unsatisfactory and disappointing. In this situation, if the development of ViroMed's VM202 completes successfully and the product gets marketed, VM202, with close-to-none competition, will be able to treat a significant number of the 1.9 million PDPN patients, 0.75 million CLI patients, and 16 million CAD patients in the US alone. As evidenced by a bulk of encouraging pre-clinical and clinical data, it may not be just optimistic thinking - it is highly likely to happen.